The company bought Kite for $12 billion last year to get access to an emerging class of cancer immunotherapies called CAR-T.

Foster City, California-based Gilead, which also makes treatments for hepatitis C among other diseases, had signaled earlier this month that it would pursue collaborations with companies for gene-editing technology.